杜瓦卢马布
放化疗
医学
阶段(地层学)
肺癌
临床研究阶段
肿瘤科
癌症
放射科
内科学
临床试验
古生物学
生物
免疫疗法
无容量
作者
Marina Chiara Garassino,Jonathan Khalifa,Martin Reck,Christos Chouaid,Helge Bischoff,N. Reinmuth,Laura Cove-Smith,T. Mansy,Diego Cortinovis,M.R. Migliorino,A. Delmonte,José García Sánchez,Luis Enrique Chara Velarde,R. Bernabe,L. Paz-Ares,P. Chander,I. Diaz Perez,K. Foroutanpour,Ugochi Emeribe,Corinne Faivre‐Finn
出处
期刊:ESMO open
[Elsevier BV]
日期:2025-05-27
卷期号:10 (6): 105071-105071
被引量:11
标识
DOI:10.1016/j.esmoop.2025.105071
摘要
Durvalumab after sCRT was well tolerated and could be an alternative treatment strategy when cCRT is not feasible. Confirmatory randomized phase III data are awaited.
科研通智能强力驱动
Strongly Powered by AbleSci AI